The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Δημοσίευση

Micro- and macrovascular treatment targets in scleroderma heart disease.

TitleMicro- and macrovascular treatment targets in scleroderma heart disease.
Publication TypeJournal Article
Year of Publication2014
AuthorsDimitroulas, T., Giannakoulas G., Karvounis H., Garyfallos A., Settas L., & Kitas G. D.
JournalCurr Pharm Des
Volume20
Issue4
Pagination536-44
Date Published2014
ISSN1873-4286
KeywordsCardiotonic Agents, Coronary Vessels, Heart, Heart Diseases, Humans, Microvessels, Molecular Targeted Therapy, Scleroderma, Systemic, Vasodilator Agents
Abstract

Cardiac involvement in systemic sclerosis (SSc) is a frequent visceral complication that considerably affects the prognosis of the disease. The pathophysiologic hallmark is myocardial fibrosis which can progress leading to arrhythmia, right and/or left heart dysfunction and failure. Symptoms range from unusual to prominent and from mild to dramatic, but clinically overt disease is a poor prognostic factor. Primary myocardial involvement is related to focal ischemia due to transient coronary spasm, and the available data support that microvascular functional and structural abnormalities rather than macrovascular coronary involvement represent the main underlying mechanism of the disease. However, the existence and prevalence of atherosclerotic coronary artery disease in SSc remain to be determined, as several studies have generated conflicting reports. Despite the lack of effective targeted therapy for SSc itself, sensitive and quantitative techniques have demonstrated the ability of vasodilators to improve myocardial function and perfusion and to prevent the evolution of subclinical heart involvement to decompensated heart failure. Further research will provide a better understanding of the disease by detecting the potent contribution of coronary artery involvement, explaining differences in accelerated atherosclerosis between SSc and other autoimmune disorders, and opening directions for the development of novel treatment strategies for this life-threatening complication of SSc.

Alternate JournalCurr. Pharm. Des.
PubMed ID23565639

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.